Business Context and Reporting Period
Company: eXoZymes Inc. (Nasdaq: EXOZ)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: eXoZymes is a pre-revenue biotechnology company developing a synthetic biology platform for the scalable production of chemical molecules. The company operates as a single reportable segment focused on research and commercialization of exozyme biosolutions. As of June 30, 2026, the company had 9,281,359 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,248,861) | $(4,216,707) |
| Net Loss Per Share (Basic & Diluted) | $(0.61) | $(0.50) |
| Cash and Cash Equivalents (Ending) | $5,652,696 | $6,985,858 |
| Net Cash Used in Operating Activities | $(3,164,719) | $(2,671,532) |
| Net Cash Provided by Financing Activities | $5,835,675 | $0 |
| Total Assets | $7,982,355 | $5,971,517 |
| Total Liabilities | $4,328,255 | $2,574,268 |
| Working Capital | $4,550,841 | $2,372,687 |
Debt and Liquidity: The company has no traditional debt but holds operating and finance lease liabilities totaling approximately $1.08 million. A significant non-cash liability of $1,902,612 was recorded for investor warrants issued in June 2026. The company maintains a cash balance of approximately $5.65 million.
Material Changes vs. Prior Period
- Increased Operating Costs: Total operating costs rose 18.7% to $5.34 million. Research and Development (R&D) costs increased 85.7% to $2.56 million, driven by higher salaries, stock-based compensation, and laboratory expenses, partially offset by a reduction in grant funding. General and Administrative (G&A) costs decreased 10.9% to $2.78 million due to lower professional fees and IT costs.
- Equity Financing: In June 2026, the company completed an underwritten public offering and a registered direct offering, raising net proceeds of $5.86 million. This resulted in the issuance of 732,260 shares of common stock and 366,130 investor warrants.
- Warrant Liability: A new warrant liability of $1.90 million was recognized in Q2 2026 related to the June offerings. This liability is classified as Level 3 fair value and is subject to remeasurement each period.
- Cash Position: Despite a net loss of $5.25 million, cash and cash equivalents increased by $2.61 million (86.0%) compared to the prior year-end, primarily due to the equity financing proceeds.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern. Current working capital is not sufficient to fund operations for the next twelve months. Future operations depend on securing additional financing through equity offerings, debt, grants, or licensing.
- Grant Funding: The company relies on government grants (NIH, NSF, DOE) which offset R&D expenses. Grant receivables decreased to $201,256. The company is pursuing additional non-dilutive funding opportunities.
- Risk Factors: Key risks include the pre-revenue status, potential inability to raise capital, supply chain disruptions, inflation, and potential U.S. tariff changes or reductions in federal research funding.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting. While remediation efforts are underway, disclosure controls were deemed not effective as of June 30, 2026.
- Unusual Items: The company recognized a $172,859 gain from the change in fair value of derivative instruments (warrants) and incurred $201,784 in offering costs during the period.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion given the "substantial doubt" disclosure and the current burn rate of approximately $3.16 million over six months.
- Warrant Liability Volatility: Monitor the fair value of the $1.9 million warrant liability, as fluctuations in stock price and volatility will directly impact net income/loss in future periods.
- Grant Sustainability: Assess the status of NIH and NSF grants and the likelihood of securing new funding to offset rising R&D costs.
- Dilution Risk: Review the terms of the 366,130 investor warrants (exercise price $11.24) and the 109,838 compensation warrants, noting the down-round protection feature that could reset the exercise price to $0.001 under certain conditions.
- Internal Control Remediation: Track the progress of remediation for the material weaknesses in internal controls to ensure future financial reporting reliability.